RxDoctor Payments Data

Melhem Solh, MD

Hematology-Oncology · Atlanta, GANPI 1023282514

Payments from drug & device makers

$4,308,122in general payments, 2019–2025

Across 1,241 payments — averaging $3471.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2.5M
  • Partner Therapeutics, Inc.$279K
  • E.r. Squibb & Sons, L.L.C.$277K
  • GSK$233K
  • ADC Therapeutics America, Inc.$175K
  • Astellas Pharma Global Development$142K
  • plus $741K from 47 others
$11,600in research payments, 2019–2025

Across 18 payments — averaging $644.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$12K

What the payments were for

  • Consulting fees$95,7988%
  • Speaking & faculty fees$912,34279%
  • Travel & lodging$107,4049%
  • Food & beverage$32,4233%
  • Education$4080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer68$2,460,766
Partner Therapeutics, Inc.13$278,865
E.r. Squibb & Sons, L.L.C.145$277,198
GSK153$233,398
ADC Therapeutics America, Inc.57$175,407
Astellas Pharma Global Development7$141,566
Amgen111$96,032
Bristol Myers Squibb114$95,424
Seagen Inc.95$92,295
Trillium Therapeutics USA, LLC3$80,818
Sanofi61$68,434
Mallinckrodt Hospital Products Inc.26$67,573
Johnson & Johnson89$62,210
AbbVie57$50,952
Merck5$47,171
National Marrow Donor Program11$27,613
Gilead(2 entities)25$13,788
Stemline Therapeutics Inc.5$5,412
Pierre Fabre Pharmaceuticals, Inc.7$5,086
Jazz Pharmaceuticals Inc.14$4,781
Genmab U.S., Inc.8$4,549
Janssen Scientific Affairs, LLC4$4,389
Legend Biotech USA Inc.15$3,676
Daiichi Sankyo Inc.8$2,999
Rigel Pharmaceuticals, Inc.12$1,125
Novartis9$1,093
Agios Pharmaceuticals, Inc.1$1,000
Astellas Pharma US Inc26$875
Beigene USA, Inc.2$672
Secura Bio, Inc.5$620
Karyopharm Therapeutics Inc.9$419
Iovance Biotherapeutics, Inc.2$296
Incyte Corporation14$289
Genentech USA, Inc.9$219
Sanofi-aventis U.S. LLC7$207
Takeda Pharmaceuticals U.S.A., Inc.6$142
Sobi, Inc7$120
Lilly USA, LLC2$94
Pharmacyclics LLC, An Abbvie Company4$74
Kyowa Kirin, Inc.2$73
Servier Pharmaceuticals LLC4$59
Morphosys, US Inc.3$52
Paratek Pharmaceuticals, Inc.3$47
Blueprint Medicines Corporation2$41
AstraZeneca2$39
Octapharma USA, Inc.2$33
Coherus Oncology, Inc.1$25
Syndax Pharmaceuticals, Inc.1$22
Acrotech Biopharma Inc.1$19
Epizyme, Inc.1$16
Melinta Therapeutics, LLC1$16
La Jolla Pharmaceutical Company1$16
Adaptive Biotechnologies Corporation1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology-oncology providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$95,632
Medicare patients
192
Services billed
3,891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate33$551,084
RezurockBelumosudil Mesylate11$267,157
CresembaIsavuconazonium Sulfate24$151,138
Posaconazole24$21,683
Atovaquone12$8,646
EliquisApixaban12$7,768
Acyclovir146$2,270
Potassium Chloride40$540
Fluconazole18$536
Levofloxacin43$297
Prochlorperazine Maleate23$269
Pantoprazole Sodium42$235
Ondansetron Hcl38$194
Dexamethasone16$182
Gabapentin25$170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$289$551,08433 claims
Sanofi-aventis U.S. LLCRezurock$207$267,15711 claims
Astellas Pharma US IncCresemba$875$151,13824 claims
PfizerEliquis$2,460,766$7,76812 claims
Lilly USA, LLCOlanzapine$94$6312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other hematology-oncology in Atlanta

Where these figures come from

Is this you, or does something look wrong? →